Amikacin Dosing in ATT-Induced Hepatitis

Standard Dosing in Hepatic Disease

The Centers for Disease Control and Prevention recommends no precautions or dose adjustments are necessary for hepatic disease alone when using amikacin, with a standard adult dose of 15 mg/kg per day (maximum 1.0 g/day) intramuscular or intravenous, initially given as a single daily dose 5-7 days per week 1, 2, 3
For patients greater than 59 years of age, the American College of Chest Physicians recommends reducing the dose to 10 mg/kg per day (750 mg maximum) 1, 3

Patients with severe hepatic disease require close renal function monitoring because they are predisposed to hepato-renal syndrome and may be at greater risk for nephrotoxicity from amikacin, according to the Centers for Disease Control and Prevention 1, 2
Serum drug concentration measurements should be obtained routinely to avoid toxicity, as recommended by the Centers for Disease Control and Prevention 1
Monthly monitoring for auditory or vestibular symptoms is essential, with audiogram and vestibular testing repeated if eighth nerve toxicity symptoms develop, according to the American Thoracic Society 3

The Centers for Disease Control and Prevention recommends reducing dosing frequency to two or three times per week, but maintaining the dose at 12-15 mg/kg per administration, to preserve the concentration-dependent bactericidal effect in patients with renal impairment 1, 2, 3
Smaller doses may reduce drug efficacy and should be avoided, according to the Centers for Disease Control and Prevention and the American College of Chest Physicians 1, 3
Dosing adjustments are essential because amikacin clearance is almost exclusively by the kidney, as stated by the Centers for Disease Control and Prevention and the American College of Chest Physicians 1, 3
For hemodialysis patients, the Centers for Disease Control and Prevention recommends administering the drug after dialysis to facilitate directly observed therapy and avoid premature drug removal 1, 3

Renal impairment occurs in 8.7% of patients receiving amikacin, with higher frequency in those with initially elevated creatinine levels, larger total doses, and concurrent nephrotoxic agents, according to the American Thoracic Society 3
In patients without risk factors, nephrotoxicity occurs in 3.4% of cases, as reported by the American Thoracic Society 3

The Centers for Disease Control and Prevention and the American College of Chest Physicians recommend not reducing the per-dose amount in renal insufficiency—only extend the dosing interval while maintaining 12-15 mg/kg per dose 1, 3
The Centers for Disease Control and Prevention recommends not assuming hepatic impairment alone requires dose reduction—amikacin undergoes renal elimination, not hepatic metabolism 1, 2
The American Thoracic Society recommends avoiding concurrent use with other nephrotoxic agents whenever possible, as this significantly increases nephrotoxicity risk 3